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Abstract
Purpose Advanced thyroid cancer responds poorly to
most therapies. New therapies and combinations are nee-
ded. The aim of this study was to examine both in vitro and
in vivo activity of two relatively new histone deacetylase
inhibitors (HDACIs), belinostat and panobinostat, and a
variety of tyrosine kinase inhibitors (TKIs) against a panel
of nine human thyroid cancer cell lines.
Methods The anti-proliferative activity and the effects of
HDACIs, TKIs and their combinations on thyroid cancer
cells were determined by cytotoxicity assays, microarray
and immunoblot analyses. Synergism between HDACIs
and TKIs was assessed by the median effects model of
Chou-Talalay (Calcusyn).
Results Belinostat and panobinostat were active against
the thyroid cancer cell lines irrespective of their mutational
composition, and belinostat was effective in preventing
growth of human thyroid cancer xenografts in immuno-
deficient mice. Further studies showed that both HDACIs
induced apoptosis. HDACI also elevated acetylated histone
3, p21Waf, and PARP, and decreased levels of phosphory-
lated ERK and AKT (Ser473). RNA assay analysis sug-
gested both HDACIs modulated genes associated with the
cell cycle, DNA damage and apoptosis. Most of the TKI
(pazopanib, motesanib, sorafenib and dasatinib) were
either inactive in vitro or were active only at high doses.
However, the novel combinations of either pazopanib or
dasatinib TKIs with either belinostat or panobinostat syn-
ergistically inhibited cell growth of thyroid cancer cells
in vitro.
Conclusions In summary, these HDACIs either alone or
combined with selected TKIs may have a role in treatment
of aggressive thyroid cancer.
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Introduction
Therapies for metastatic advanced thyroid cancers are
inadequate with most therapeutic approaches failing to
produce meaningful long-term responses (Smallridge et al.
2009; Licitra et al. 2010). The relatively modest response
rates with tyrosine kinase inhibitors (TKIs) have led to sev-
eral ongoing trials using combinations of TKIs with other
targeted agents in an effort to improve the clinical outcome
(Cohen et al. 2008; Gupta-Abramson et al. 2008; Sherman
et al. 2008; Schlumberger et al. 2009; Bible et al. 2010).
Histone deacetylase inhibitors (HDACIs) are a promis-
ing class of drugs in thyroid cancer; in vitro and in vivo
studies of vorinostat (SAHA) (Luong et al. 2006) showed
that this agent is active against human thyroid cancer cell
lines. However, data suggest that single-agent HDACIs may
not be a viable treatment strategy in solid cancers (Ellis and
Pili 2010; Woyach et al. 2009; Venugopal and Evans 2011).
As such, a number of trials are pursuing combinations of
HDACIs with other agents both in thyroid cancer and other
types of solid malignancies (Munster et al. 2011). In this
study, we tested two relatively new HDACIs (belinostat and
panobinostat) and multiple TKIs alone and in combination
against a panel of nine human thyroid cancer cell lines that
have been validated as to their accuracy (Schweppe et al.
2008); these HDACIs appear active both in vitro and in vivo
(belinostat) and appear to have enhanced activity when
combined with one of several TKIs.
Materials and methods
Reagents
Belinostat and panobinostat (HDACIs) were obtained from
National Cancer Institute (NCI, USA) and Selleck Chem-
icals (Boston, MA), respectively. Pazopanib, motesanib,
sorafenib and dasatinib (TKIs) (LC Laboratories) were
dissolved in DMSO and stored in aliquots at -20 C until
use. Antibodies to acetylated histone H3 (AcH3), p21Waf1,
PARP, pAKT (Ser473), pERK, AKT, ERK and GAPDH
were obtained from Cell Signaling Technology (MA,
USA).
Cell lines and culture
Cal62 (anaplastic—KRAS G12R mutant), SW1736 (ana-
plastic—BRAF mutant), T238 (anaplastic—PI3K and
BRAF mutant), Hth7 (anaplastic—NRAS Q61R), T241
(unknown—no mutation), T351 (unknown—no mutation),
C643 (anaplastic—HRAS G13R), BHP2-7 (papillary—
RET/PTC rearrangements) and Hth83 (unknown—HRAS
G13R) were generously provided by Dr. James A. Fagin
(Memorial Sloan Kettering Cancer Center, New York,
USA). Hth7 was grown in DMEM with 10 % fetal bovine
serum (Hyclone, Logan, UT). The rests of the cell lines
were maintained in RPMI (Life Technologies, Carlsbad,
CA) containing 10 % fetal bovine serum, 1 % penicillin–
streptomycin and 1 % glutamine with the exception of
SW1736, which was supplemented with 1 % MEM non-
essential amino acid. All cells were grown at 37 C and
5 % CO2.
Cytotoxicity assay
For measurement of cell viability, 1.0–5.0 9 103 cells
were plated in 96-well flat-bottomed microtiter plates and
grown overnight at 37 C. The following day, the cells
were treated with 10 ll of various concentrations of either
HDAC inhibitors/TKI/combination or vehicle and incu-
bated for 48/72 h. After 48/72 h, 250 lg of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
(Sigma-Aldrich) was added to each well and incubated at
37 C for 2–4 h, after which 100 ll of DMSO was added,
as previously reported (Chan et al. 2012). Absorbance was
measured with a Tecan Infinite 200 PRO spectrophotom-
eter (Mannedorf, Switzerland) at a wavelength of 595 nm.
As previously mentioned, the percentage viability at each
drug concentration was calculated using the following
formula:
ðAbsorbance of treated cells  Absorbance of mediaÞ
ðAbsorbance of untreated cells  Absorbance of mediaÞ
The percentage values obtained were then plotted using
GraphPad Prism software nonlinear regression (curve fit)
to obtain the half maximal inhibitory concentration (IC50)
and its 95 % confidence interval (CI).
The dose ranges tested: belinostat (100–10,000 nM);
panobinostat (1–2,000 nM); dasatinib (1–300 nM); so-
rafenib, pazopanib and motesanib (100–5,000 nM).
Assessment of synergism by the median effects model
of Chou-Talalay (Calcusyn)
The combinations of HDACIs and TKIs were assessed by
the median effects model of Chou-Talalay using Calcusyn
software from BioSoft. The interpretation of the nor-
malized isobolograms and interpretation of the degree of
synergism is as per the combination index (CI) stated in
Supporting Information Fig. S1.
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Gene expression profiling and analysis
Using Affymetrix Human Gene 1.0ST array (Affymetrix,
Santa Clara, CA), mRNA expression profiling was done in
either biological triplicates (for BHP control and BHP
panobinostat 100 nM, 30 h) or biological duplicates (BHP
belinostat 50 lM, 30 h). Total RNA was reversed tran-
scribed, amplified and labeled according to manufacturer’s
protocol. Labeled cDNA was hybridized onto Human
Gene 1.0ST array for 16 h at 60 rpm in a GeneChip
Hybridization Oven 640 (Affymetrix). Following manu-
facturer’s instructions, the arrays were washed and scan-
ned using GeneChip Scanner 3000 7G. The CEL files
were imported into GeneSpring Software V11 for data
normalization and identification of differentially expressed
mRNAs of interest. As mentioned previously, the CEL
files were preprocessed using RMA16 algorithm and
CORE transcript level. Data were quantile normalized,
and those expression values less than the 20th percentile
were filtered out. A list of differentially expressed mRNAs
of interest was generated using the fold change function
(Chan et al. 2012). Using hierarchical clustering, heatmaps
were generated and gene ontology analysis was done
using GO. To understand further the biological functions
of the differentially expressed genes, Web-based software,
MetaCore (GeneGo, St. Joseph, MI), was used to perform
gene ontology and pathway/network analysis as mentioned
previously (Chan et al. 2012). Several algorithms to
enable both the construction and analysis of gene
networks were integrated as previously described (Ekins
et al. 2007).
Western blotting
Lysates were collected from cells treated with HDAC
inhibitor for 30 h. Briefly, cells were lysed at 4 C in RIPA
lysis buffer, and the insoluble material was removed by
centrifugation at 4 C, 10,000g for 10 min. Proteins in the
cell lysates were quantified by Bradford Assay. Forty
micrograms of protein from each sample was resolved by
SDS-PAGE and electroblotted to Immobilon-P Transfer
Membranes (Millipore, Billerica, MA). Membranes were
probed with the various primary antibodies from Cell
Signaling Technologies. Following binding of the primary
antibodies, horseradish peroxidase (HRP)-conjugated anti-
rabbit/anti-mouse secondary antibodies were introduced to
the membrane. Bound secondary antibody was detected by
using Amersham ECL Plus Western blotting detection
reagents (GE Healthcare, USA). Membranes were stripped
and probed for GAPDH as loading controls or the
non-phosphorylated protein (where applicable) (Chan et al.
2012).
Apoptosis assay
According to the instructions from the manufacturer, 105
cells were treated with either belinostat or panobinostat for
48 h and labeled with FITC-conjugated annexin V anti-
body and propidium iodide (PI) using annexin V–FITC
Apoptosis Detection kit I (BD Biosciences, San Jose).
Positive cells were detected by fluorescence-activated cell
sorting as mentioned previously (Chan et al. 2012).
Murine studies
All mice were fed a standard chow diet. Six-week-old
female athymic nu/nu mice—NCRFU—were purchased
from Taconic Hudson (NY). Upon arrival, these animals
were quarantined for 1 week in the animal facility and
maintained in a 12 h light/dark cycle, with free access to
food and water.
Mice were anaesthetized with inhalational isoflurane
(Hospira Lakeforest, IL). BHP2-7 cells (2 9 107) were
resuspended in 50 ll Matrigel (BD Biosciences) and 50 ll
PBS for each tumor. Cells were injected subcutaneously on
both flanks of the immunodeficient mice. A total of 32
tumors were inoculated (8 in control and 8 in drug treatment
mice). Mice were injected with belinostat intraperitoneal
(Cheung et al. 2003) (100 mg/kg/injection), 5 days a week
for 3 weeks starting on day 3. The weight of the mice was
measured every week. At the end of either drug or vehicle-
only treatment (52 days after tumor cell injection), animals
were killed by CO2 inhalation, tumor dissected and volumes
calculated according to the formula: (length 9
width 9 thickness 9 0.5236) (Chan et al. 2012). During the
experiment, external measurements were made in millime-
ters using vernier callipers. At completion of the study,
tumors were formalin-fixed and processed for histological
and immunohistochemical (IHC) analyses. Murine studies
were approved by the Animal Care and Use Committee of
Cedars-Sinai Medical Center, and all animal care was in
accordance with the IACUC guidelines.
Results
Cytotoxicity assay
To assess the anti-proliferative activity of either the
HDACIs or TKIs, dose–response studies were performed
using MTT assay. Mean proportion viability of the cells at
each drug concentration was plotted using GraphPad Prism
software, and the drug dose that inhibited 50 % growth
(relative to vehicle-treated control) [IC50] at 72 h of culture
was obtained from the software (nonlinear regression curve
fit). For range of drug testing, the pharmacologically
J Cancer Res Clin Oncol (2013) 139:1507–1514 1509
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relevant doses of each of the drugs were inferred from
phase I clinical trials (see ‘‘Materials and methods’’) (Giles
et al. 2006; Hurwitz et al. 2009; Minami et al. 2008; De-
metri et al. 2009; Schlumberger et al. 2009; Steele et al.
2008). Both belinostat and panobinostat reduced thyroid
cancer cell viability in vitro in 8 of the 9 cell lines tested at
a pharmacologically achievable dose; the PI3K ? BRAF
mutant (T238) cell line was resistant to panobinostat
(Table 1). Only sorafenib [8 of 9 cell lines (IC50 5.0–13
lM)], pazopanib [1 of 9 cell lines (IC50 3.4 ± 0.2 lM)]
and dasatinib [2 of 9 cell lines, (IC50 47 ± 3 and
35 ± 5 nM)] were effective among the TKIs (Table 1).
Belinostat- and panobinostat-treated BHP2-7 thyroid
cancer cell line has overlapping mRNA changes
In order to gain insights into which common pathways is
altered by the two HDACIs, BHP2-7 cells were exposed to
either belinostat 50 lM or panobinostat 100 nM for 30 h.
RNA was extracted and subjected to microarray analysis
(Supporting Information Table S1). Only genes with
Ctwofold change (panobinostat treatment) or Cfourfold
change (belinostat treatment) were deemed to be signifi-
cantly altered. Among the 528 and 573 altered genes for
panobinostat and for belinostat, respectively, 153 of these
genes were commonly altered. These 153 genes constituted
3 main pathways: cell cycle-related, DNA damage and
apoptosis (Supporting Information Fig. S2) which promp-
ted additional studies.
Belinostat and panobinostat treatment-related protein
changes
Both belinostat and panobinostat caused acetylation of
histone H3 and induced the expression of p21Waf1 in four
representative thyroid cancer cell lines (Cal62, SW1736,
T238 and BHP2-7) irrespective of their mutational com-
position (Fig. 1, Panel a). Of note, T238 cells were rela-
tively resistant to growth inhibition by the HDACIs and
had minimal induction of p21. Protein changes in the RAS-
RAF-MEK-ERK and PI3K-AKT-mTOR pathways due to
HDACIs were examined as these are important signaling
proteins in thyroid cancer. Reduced levels of both pERK
and pAKT were observed in all four thyroid cancer lines
with both belinostat and panobinostat treatments (Fig. 1,
Panel b). Also, both HDACIs caused apoptosis as measured
by cleaved PARP (Fig. 1, Panel c). [No cleaved PARP was
detectable in resistant T238 cultured with panobinostat 100
nM.]
Annexin V/propidium iodide assay
Consistent with the detection of cleaved PARP observed on
Western blot, belinostat (50 lM) and panobinostat
(100 nM) (30 h) induced early and late apoptosis in the
BHP2-7, Cal62 and SW1736 thyroid cancer cell lines as
measured by annexin V/propidium measurements
(Table 2). Panobinostat (100 nM) resulted in less apoptosis
(11–37 %) than belinostat (50 lM) (43–68 %). Consistent
with the Western blot data, the T238 cell line had fewer
apoptotic cells after culture with either panobinostat (3 %)
or belinostat (24 %) as compared to the other HDACI-
treated cell lines (Table 2).
Human thyroid cancer xenograft study
Belinostat was injected intraperitoneally into immunode-
ficient mice carrying BHP2-7 xenografts (100 mg/kg/day,
5 days/week, 52 days). Prominent inhibition of growth of
the tumors occurred in the experimental mice compared to















Cal62 KRAS 470 ± 36 33 ± 4 35 ± 5 13 ± 1.1 NR NR
Hth7 NRAS 400 ± 56 15 ± 2 NR 6.8 ± 0.8 NR NR
Hth83 HRAS 720 ± 100 34 ± 5 NR 11 ± 1.0 NR NR
C643 HRAS 970 ± 120 71 ± 10 NR 6.5 ± 0.9 NR NR
SW1736 BRAF 380 ± 40 35 ± 8 NR NR NR NR
T241 Nil 750 ± 65 65 ± 7 NR 7.5 ± 0.5 NR NR
T351 Nil 1,100 ± 170 50 ± 10 NR 11 ± 2.0 NR NR
BHP2-7 RET/PTC 770 ± 67 37 ± 6 47 ± 3 5.0 ± 0.8 340 ± 20 NR
T238 PI3 K/BRAF 6,800 ± 740 1,500 ± 200 NR 6.5 ± 1.2 NR NR
Tabulated results of HDACI (belinostat and panobinostat) and tyrosine kinase inhibitor (TKI dasatinib, sorafenib, pazopanib and motesanib)-
treated thyroid cancer cell lines at 72 h of drug exposure. Mean 50 % inhibitory concentration (IC50 ± SD) of experiments done in triplicate
experiments with each experiment done with triplicate wells using MTT assay. Nil: No mutations detected. NR: IC50 not reached (i.e.,
pharmacologically relevant IC50 not reached). See ‘‘Materials and methods’’ for details
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control mice receiving diluent alone (Fig. 2a). Experi-
mental mice did not lose body weight (Fig. 2b) and
appeared and behaved normally during the study.
TKIs and their combination with either belinostat
or panobinostat with TKIs
Combinations of either belinostat or panobinostat with one
of the TKIs (see Table 1) were tested against 3 thyroid
cancer cell lines and assessed by MTT assay and Calcu-
syn analysis (Table 3a–c). HDACI–sorafenib combina-
tions were antagonistic, while motesanib-HDACI
combinations were only additive (data not shown). How-
ever, either belinostat or panobinostat with either dasatinib
or pazopanib was synergistic in their anti-proliferative
activity against BHP2-7 (RET/PTC rearrangement), Cal62
(KRAS mutant) and SW1736 (BRAF mutant) thyroid
cancer cells. The degree of synergism varied among the
above combinations but was strongest for the Cal62 cell
line [i.e., combination index (CI) was lowest] (interpreta-
tion of the combination index appears on Supporting
Information Fig. S1).
Discussion
We found that belinostat and panobinostat inhibited growth
in vitro, induced apoptosis and dephosphorylated AKT and
ERK in a panel of thyroid cancer cell lines; and belinostat
remarkably inhibited tumor growth in mice carrying thy-
roid cancer xenografts. Studies have shown that this family
of drugs can have a myriad of effects (Dokmanovic et al.
2007). As their name implies, they can reverse the activity
of HDAC, causing acetylation of histones which opens the
chromatin to allow transcription of a large array of genes.
Furthermore, these compounds can acetylate numerous
proteins resulting in change of their function (Bolden et al.
2006). Our microarray analysis of BHP2-7 treated with
either belinostat or panobinostat showed modulation of
genes involved in pathways associated with the cell cycle,
DNA damage and apoptosis-related processes.
The HDACIs acetylated H3 protein in the four repre-
sentative cell lines, including T238 which were resistant to
growth inhibition by HDACI (especially panobinostat)
(Fig. 1). These cells had minimal induction of p21, sug-
gesting that this cyclin kinase inhibitor may potentially
represent a biomarker of growth inhibition by the HDACI.
Various in vitro studies of MAPK and PI3K/AKT inhibitor
monotherapy have shown conflicting results in thyroid
Fig. 1 Immunoblots of thyroid cancer cell lines (BHP2-7, SW1736,
T238 and Cal 62) treated with either belinostat 50 lM (Bel),
panobinostat 100nM (Pan) or diluent control (Cont) (30 h) and
analyzed for expression levels of various proteins. (a) Phosphorylated
pAKT and pERK. (b) And cleaved PARP (arrowhead)









Cal62 3 37 68
SW1736 3 11 56
BHP2-7 5 16 43
T238 2 3 24
Combined early and late apoptosis results [annexin V early and
propidium iodine (late) positive measured by FACS] (expressed as
percentage of total number of cells) tabulated for BHP2-7, Cal62,
SW1736 and T238 cell lines after 30-h culture. Results represent the
mean of triplicate cultures. Means did not vary more than 10 %
between experiments
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cancer (depending on mutational status and growth con-
ditions) (Schweppe et al. 2009). However, combinations of
agents blocking both the PI3K-AKT-mTOR and MAPK
pathways show greater anti-proliferative activity (Jin et al.
2009) and are now in clinical trials (e.g., combinations of
sorafenib and everolimus) [www.clinicaltrial.gov]. We
show that both belinostat and panobinostat markedly
inhibited activation of both of these pathways in the four
representative thyroid cancer cell lines. But T238 cells
were resistant to growth inhibition by the HDACIs
Fig. 2 Effect of belinostat on
proliferation of human thyroid
cancer xenografts growing in
athymic mice. Graph of mean
xenograft tumor volume (mm3)
in belinostat-treated (100 mg/
kg/5 day per week, I.P.) versus
vehicle control-treated (treated
similarly) mice over 52 days.
Sixteen tumors (BHP2-7) were
in both groups. (a) Graph of
mean weights (in grams) of
mice in the belinostat-treated
and control-treated groups over
the duration of experiment (b)
Table 3 Combination index of (a) belinostat/panobinostat and dasatinib on SW1736 cells, (b) belinostat/panobinostat and dasatinib on Cal 62
cells, (c) belinostat/panobinostat and pazopanib on BHP 2-7 cells
Dasatinib (nM) Belinostat (nM) Panobinostat (nM)
(a)
250 500 750 1,000 1 20 40 50
100 0.47 0.41 0.39 0.29 0.14 0.48 0.54 0.56
Dasatinib (nM) Belinostat (nM) Panobinostat (nM)
(b)
250 500 750 1,000 8 16 24 45
100 0.13 0.14 0.15 0.14 0.17 0.16 0.18 0.29
Pazopanib (lM) Belinostat Panobinostat





Combination index described more fully in Fig. S1. Values B0.90 are consistent with synergism, and the lower the value, the greater the
synergism
1512 J Cancer Res Clin Oncol (2013) 139:1507–1514
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suggesting that inhibition of either phosphor-AKT or
phosphor-ERK does not assure that the HDACI will be
growth inhibitory.
One notable characteristic of thyroid cells is the ability
to exchange extracellular iodine (I) for intracellular sodium
(Na) by way of the Na/I symporter. The intracellular iodine
has to be organified for it to stay in the cell rather than
efflux out. While well-differentiated metastatic thyroid
cancer can be treated with 131I which is selectively taken
up by the thyroid Na/I symporter, radioiodine-resistant
thyroid cancers are not amenable to this form of therapy.
We found that belinostat and panobinostat could induce
both Na/I symporter mRNA and protein in thyroid cancer
cells, but the levels of intracellular 131I accumulation were
low even though TPO was induced by these HDACIs (data
not shown).
In recent years, phase II clinical trials of various small
molecule tyrosine kinase inhibitors (including sorafenib,
motesanib and pazopanib) (Gupta-Abramson et al. 2008;
Sherman et al. 2008; Bible et al. 2010) have shown modest
activity against thyroid cancers (mainly stabilization dis-
ease by RECIST criteria) (Cabanillas et al. 2010). The
exact mechanism of action of these agents is still uncertain
given the poor correlation between the predicted in vitro
targets (e.g., RET and BRAF inhibitors) of these agents,
mutational status of the tumors (RET and BRAF muta-
tions) and clinical response. Of note, the RECIST clinical
response rates of the above mentioned kinases are all
remarkably similar in spite of the differences in spectrum
of their kinase targets. The lack of efficacy of the tested
TKIs is not surprising given our previous study (Chan et al.
2012) which showed that most thyroid cancer cell lines are
either resistant to a large number of TKIs or else are
effective only at high IC50 which are not pharmacologi-
cally relevant. A prior in vitro and in vivo study of so-
rafenib (Salvatore et al. 2006) showing that it was effective
against a panel of BRAF V600E thyroid cancer cell lines is
now known to have been confounded by the fact that most
of the tested cell lines were not thyroid in origin (Schweppe
et al. 2008) and that sorafenib is not a potent BRAF
inhibitor.
The sensitivity of BHP2-7 (RET/PTC rearrangement) to
pazopanib as well as the sensitivity of BHP2-7 and the
KRAS mutant Cal62 cell line to dasatinib within the
pharmacological range merits further study. The lack of
efficacy of sorafenib against SW1736 (BRAF mutant) that
we observed is now known to be due to the fact that so-
rafenib does not have potent anti-BRAF properties
(Smalley and Flaherty 2009). Trials of PLX4032 in thyroid
cancer, a proven potent BRAF inhibitor in melanoma, have
recently been shown to have poor activity against RAS or
RET mutants (Salerno et al. 2010). This is partly due to the
paradoxical ability of Raf inhibitors to stimulate wild-type
Raf to activate the MAPK pathway and enhance growth of
these tumors (Hatzivassiliou et al. 2010).
The synergistic anti-proliferative activity of either beli-
nostat or panobinostat combined with either pazopanib or
dasatinib in the thyroid cancers carrying either RET/PTC1
rearrangement (BHP2-7), KRAS G12R mutation (Cal62)
or BRAF V600E mutation (SW1736) is of interest. The
mutations in these three lines are important components in
the MAPK cascade. We found that the downstream path-
ways of these oncogenes could be inhibited by the HDACI,
and thus, the TKI and HDACI may work in unison
resulting in their anti-proliferative activity.
In summary, belinostat and panobinostat were effective
against a wide range of thyroid cancer cell lines irrespective
of their mutational composition (with the possible excep-
tion of the PI3K mutant, T238 cell line). This, in concert
with the activity of belinostat to suppress the growth of
thyroid cancer xenografts in athymic nude mice with no
obvious side effects, suggests that clinical studies with these
HDACs should be pursued. Furthermore, the synergistic
combination of HDAC inhibitors-TKIs has previously not
been reported and might present a clinical opportunity.
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